The Claim
Molecular docking simulations predict stable binding between aspartame and the protein products of eight genes (APLNR, CYP2C19, EDNRA, KLK5, F2R, RAD51, AURKA, TLR2) implicated in kidney renal papillary cell carcinoma, with binding energies below −5.0 kcal/mol.
What the research says
Not yet evaluated
We are still looking at what the research says.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Computer simulations show that aspartame binds strongly to eight proteins linked to a type of kidney cancer, with binding strength below −5.0 kcal/mol.
See the scientific wording
Molecular docking simulations predict stable binding between aspartame and the protein products of eight genes (APLNR, CYP2C19, EDNRA, KLK5, F2R, RAD51, AURKA, TLR2) implicated in kidney renal papillary cell carcinoma, with binding energies below −5.0 kcal/mol, suggesting these proteins may be direct molecular targets of aspartame.
Aspartame sticks to eight proteins in kidney cells, which stops some from doing their normal jobs and overactivates others. This causes cells to multiply too fast, repair DNA poorly, invade surrounding tissue, and trigger chronic inflammation, all of which lead to kidney cancer.
What the research says
1 studyComputer simulations show that aspartame might stick to eight proteins linked to a type of kidney cancer, which could interfere with how they work — but this hasn’t been proven in real cells or people yet.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.